TY - JOUR
T1 - Defining a Path Toward the Use of Fast-Scan Cyclic Voltammetry in Human Studies
AU - Lucio Boschen, Suelen
AU - Trevathan, James
AU - Hara, Seth A.
AU - Asp, Anders
AU - Lujan, J. Luis
N1 - Funding Information:
This work was supported by the National Institutes of Health, NINDS (R01 NS084975 award to JLL) and The Grainger Foundation.
Publisher Copyright:
Copyright © 2021 Lucio Boschen, Trevathan, Hara, Asp and Lujan.
PY - 2021/11/12
Y1 - 2021/11/12
N2 - Fast Scan Cyclic Voltammetry (FSCV) has been used for decades as a neurochemical tool for in vivo detection of phasic changes in electroactive neurotransmitters in animal models. Recently, multiple research groups have initiated human neurochemical studies using FSCV or demonstrated interest in bringing FSCV into clinical use. However, there remain technical challenges that limit clinical implementation of FSCV by creating barriers to appropriate scientific rigor and patient safety. In order to progress with clinical FSCV, these limitations must be first addressed through (1) appropriate pre-clinical studies to ensure accurate measurement of neurotransmitters and (2) the application of a risk management framework to assess patient safety. The intent of this work is to bring awareness of the current issues associated with FSCV to the scientific, engineering, and clinical communities and encourage them to seek solutions or alternatives that ensure data accuracy, rigor and reproducibility, and patient safety.
AB - Fast Scan Cyclic Voltammetry (FSCV) has been used for decades as a neurochemical tool for in vivo detection of phasic changes in electroactive neurotransmitters in animal models. Recently, multiple research groups have initiated human neurochemical studies using FSCV or demonstrated interest in bringing FSCV into clinical use. However, there remain technical challenges that limit clinical implementation of FSCV by creating barriers to appropriate scientific rigor and patient safety. In order to progress with clinical FSCV, these limitations must be first addressed through (1) appropriate pre-clinical studies to ensure accurate measurement of neurotransmitters and (2) the application of a risk management framework to assess patient safety. The intent of this work is to bring awareness of the current issues associated with FSCV to the scientific, engineering, and clinical communities and encourage them to seek solutions or alternatives that ensure data accuracy, rigor and reproducibility, and patient safety.
KW - clinical neurochemistry
KW - deep brain stimulation
KW - fast scan cyclic voltammetry
KW - intraoperative
KW - neurochemical signaling
KW - neurophysiology
UR - http://www.scopus.com/inward/record.url?scp=85120420857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120420857&partnerID=8YFLogxK
U2 - 10.3389/fnins.2021.728092
DO - 10.3389/fnins.2021.728092
M3 - Review article
AN - SCOPUS:85120420857
SN - 1662-4548
VL - 15
JO - Frontiers in Neuroscience
JF - Frontiers in Neuroscience
M1 - 728092
ER -